Arrowhead Pharmaceuticals (ARWR) Cash from Financing Activities (2010 - 2026)

Arrowhead Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $795.7 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 761.33% year-over-year to $795.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $742.0 million (up 34.29% YoY) and the FY2025 annual result came in at $74.0 million, down 91.5% from the prior year.
• Cash from Financing Activities was $795.7 million for Q1 2026 at Arrowhead Pharmaceuticals, up from -$14.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $795.7 million in Q1 2026 and bottomed at -$42.7 million in Q2 2025.
• A 5-year average of $120.1 million and a median of $3.7 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 82741.73% — and 2025, when it tumbled 184.7%.
• Arrowhead Pharmaceuticals' Cash from Financing Activities stood at $250.6 million in 2022, then plunged by 99.89% to $267000.0 in 2023, then soared by 7628.09% to $20.6 million in 2024, then tumbled by 171.48% to -$14.8 million in 2025, then surged by 5494.69% to $795.7 million in 2026.
• Business Quant data shows ARWR's Cash from Financing Activities at $795.7 million in Q1 2026, -$14.8 million in Q4 2025, and $3.7 million in Q3 2025.